Searle’s Denosumab biosimilar gains regulatory approval

September 10, 2025 (MLN): Searle Company Limited has reached a major milestone as Denosumab, Pakistan’s first biosimilar of its kind, receives regulatory approval. 

This development marked a transformative moment in the country’s pharmaceutical sector as it introduced a locally developed biotechnological therapy that expands access and affordability for patients nationwide.

Denosumab, a monoclonal antibody used to treat osteoporosis and cancer-related bone conditions, now enters the market in biosimilar form, offering a cost-effective alternative to imported treatments.

Patients previously burdened by high prices may now benefit from the broader availability of this advanced therapy.

“This approval reflects a commitment to innovation and patient-focused healthcare,” the company stated. “It signals progress toward greater accessibility and long-term value creation.”

It will potentially reshape the biotech landscape and encourage investment in local research and manufacturing.

Copyright Mettis Link News